Literature DB >> 8573964

Cisapride for the treatment of chronic idiopathic constipation.

V Y Gardner1, J V Beckwith, C A Heyneman.   

Abstract

Cisapride appears to be useful as therapy for chronic constipation that is not associated with underlying organic abnormalities or pregnancy and that is refractory to other treatments, such as increased dietary fiber intake or bulk laxatives. Dosages of cisapride that have demonstrated efficacy in chronic constipation range from 5 mg po tid to 20 mg po bid. Treatment for 8-12 weeks may be necessary for an optimal effect to occur. Further studies are needed to evaluate the most effective dosage regimen for the treatment of constipation and to compare the efficacy and cost-efficiency of cisapride with those of conventional therapy. Until these studies are completed, cisapride should not be recommended routinely for patients with constipation. However, it may be a viable option for patients with chronic idiopathic constipation that is refractory to conventional therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8573964     DOI: 10.1177/106002809502901117

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

1.  Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans.

Authors:  E P Bouras; M Camilleri; D D Burton; S McKinzie
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

2.  Prucalopride-associated acute tubular necrosis.

Authors:  Vithika Sivabalasundaram; Flavio Habal; David Cherney
Journal:  World J Clin Cases       Date:  2014-08-16       Impact factor: 1.337

Review 3.  Adult constipation: a review and clinical guide.

Authors:  T Q Jacobs; R J Pamies
Journal:  J Natl Med Assoc       Date:  2001-01       Impact factor: 1.798

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.